Cargando…

Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy

The purpose of this study was to evaluate prediction of prognosis after first-line radioimmunotherapy (RIT) of advanced follicular non-Hodgkin lymphoma (FL), by imaging with fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography ((18)F-FDG-PET/CT) three months after ind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kesavan, Murali, Boucek, Jan, MacDonald, William, McQuillan, Andrew, Turner, J. Harvey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489946/ https://www.ncbi.nlm.nih.gov/pubmed/28498337 http://dx.doi.org/10.3390/diagnostics7020026

Ejemplares similares

Standard Operating Procedure for In-house Preparation of (131)I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Pickford, Matthew D., et al.
Publicado: (2012)

Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin’s lymphoma
por: Andemariam, Biree, et al.
Publicado: (2007)

Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Calais, Phillipe J., et al.
Publicado: (2012)

Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin’s lymphoma
por: Burdick, Michael J, et al.
Publicado: (2009)

Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
por: Buchegger, Franz, et al.
Publicado: (2011)

Development of DOTA-Rituximab to be Labeled with (90)Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
por: Johari doha, Fariba, et al.
Publicado: (2017)

Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
por: Bodet-Milin, Caroline, et al.
Publicado: (2013)

Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with (90)Y and (111)In for domestic radioimmunotherapy and radioscintigraphy of Non-Hodgkin’s Lymphoma
por: Gholipour, Nazila, et al.
Publicado: (2014)

The role of (18)F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using (131)I-rituximab as consolidation therapy
por: Choi, Joon Ho, et al.
Publicado: (2022)

Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice
por: Lin, Ruoting, et al.
Publicado: (2021)

Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma
por: Ansell, Stephen M., et al.
Publicado: (2011)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma
por: Burack, W. Richard, et al.
Publicado: (2023)

Radioimmunotherapy of Non-Hodgkin’s Lymphoma: From the ‘Magic Bullets’ to ‘Radioactive Magic Bullets’
por: Chamarthy, Murthy R., et al.
Publicado: (2011)

Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar
por: Sachpekidis, Christos, et al.
Publicado: (2019)

Maintenance rituximab in Veterans with follicular lymphoma
por: Halwani, Ahmad S., et al.
Publicado: (2020)

Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

An approach for conjugation of (177)Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients
por: Thakral, Parul, et al.
Publicado: (2014)

Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma: A NICE Single Technology Appraisal
por: Greenhalgh, Janette, et al.
Publicado: (2013)

Rituximab induced hypoglycemia in non-Hodgkin's lymphoma
por: Hussain, Badrudeen M, et al.
Publicado: (2006)

Radioimmunotherapy-based conditioning regimen prior to autologous stem cell transplantation in non-Hodgkin lymphoma
por: Eskian, Mahsa, et al.
Publicado: (2018)

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma
por: Herrera, Alex F., et al.
Publicado: (2021)

Radioimmunotherapy of human hepatocellular carcinoma xenografts with 131I-labelled antiferritin antibody.
por: Saiful Alam, A. F.
Publicado: (1991)

Radioimmunotherapy study of (131)I-labeled Atezolizumab in preclinical models of colorectal cancer
por: Zhang, Linhan, et al.
Publicado: (2022)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
Publicado: (2023)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
por: Li, Ru, et al.
Publicado: (2022)

Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy
por: Gritti, Giuseppe, et al.
Publicado: (2018)

Rituximab maintenance therapy of follicular lymphoma in clinical practice
por: Dührsen, Ulrich, et al.
Publicado: (2018)

Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma
por: Kesavan, Murali, et al.
Publicado: (2019)

Expanded use of rituximab in the management of non-Hodgkin lymphoma
por: Eichenauer, Dennis A, et al.
Publicado: (2009)

Iodine-131 and Thyroid Function
por: Sun, Wenjie
Publicado: (2014)

Radioimmunotherapy of transplanted small cell lung cancer with 131I-labelled monoclonal antibody.
por: Yoneda, S., et al.
Publicado: (1988)

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
por: Muylle, Kristoff, et al.
Publicado: (2015)

Correction: Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy
por: Gritt, Giuseppe, et al.
Publicado: (2018)

Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma
por: Aguiar-Bujanda, David, et al.
Publicado: (2015)

B cell non-Hodgkin's lymphoma: rituximab safety experience
por: Mohrbacher, Ann
Publicado: (2005)

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
por: Leslie, Lori A.
Publicado: (2021)

Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up
por: Soini, E. J. O., et al.
Publicado: (2011)

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
por: Kim, Hee Kyung, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p0lsaqome73l4nq965ll0a1302